Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 12 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

2 trials in Phase 3/4

Results Transparency

18%

2 of 11 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A

3(60.0%)

Phase 3

1(20.0%)

Phase 4

1(20.0%)

5Total

N/A(3)

Phase 3(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials

NCT07294911Completed

Predictors of Contrast-induced Acute Renal Injury in Patients With Acute Coronary Syndrome

Role: lead

NCT06937346Not ApplicableCompleted

Rehabilitation Robotic System ReHand

Role: lead

NCT07029048Completed

Oxidative Stress and Cognitive Dysfunction After COVID-19

Role: lead

NCT05229822Completed

Bacterial Translocation Markers as Predictors of Infectious and Inflammatory Complications in Acute Bowel Obstruction

Role: lead

NCT06460753Completed

Analysis of Laboratory Markers for Severe COVID-19

Role: lead

NCT06397430Not ApplicableCompleted

Nutritional Support for Patients Operated for Malignant Tumors in HPD Zone

Role: lead

NCT06221293Active Not Recruiting

Correlation Between Intra-abdominal Pressure, Biomarkers of Bacterial Translocation and Intestinal Wall Damage

Role: lead

NCT05431218Phase 4Completed

Association of Cathelicidin and Vitamin D Levels With the Category and Course of COPD

Role: lead

NCT05222893Not ApplicableCompleted

Optimization of PEEP During Laparoscopic Surgery

Role: lead

NCT04871841Completed

Study of Sputnik V COVID-19 Vaccination in Adults in Kazakhstan

Role: lead

NCT05704569Completed

Prediction of Primary Cardiovascular Events Using the Multimarker Approach

Role: lead

NCT02607449Phase 3Completed

FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis

Role: collaborator

All 12 trials loaded